ly3300054
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 29, 2016 (NCT02791334)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ly3300054
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03495323 | Phase 1 | May 16, 2018 | Eli Lilly, Harvard University |
| NCT03343613 | Phase 1 | Nov 17, 2017 | Eli Lilly |
| NCT02791334 | Phase 1 | Jun 29, 2016 | Eli Lilly |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 3 | 2 | 1 | 2016 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1